The U.S. Food and Drug Administration has announced its interest in considering the use of electronic health records with electronic data capture in order to improve clinical trials for new and investigational drugs.
Researchers have shown how easy it is to re-identify patients in de-identified data, yet de-identified data can lose its value as more identifying factors are stripped out.
Figuring out how to piece together data from a hodgepodge of clinical studies will be one of the first items on the agenda for President Barack Obama's Precision Medicine initiative, according to Francis Collins, director of the National Institutes of Health.
The University of Washington health system and Seattle Cancer Care Alliance plan to start seeking patient consent to have medical records and leftover blood or tissue made available for future research.
A multi-stakeholder effort is necessary to create the culture, infrastructure and policies needed to further responsible data-sharing for clinical trials, an Institute of Medicine report finds.
The U.S. Department of Health and Human Services and the National Institutes of Health have proposed new rules for clinical trials that clarify requirements for registering the trials and submitting trial results online at ClinicalTrials.gov.
Using mobile tools in clinical trials offers a long list of benefits, from helping patients stay on medication routines to the ability to change gears in quick fashion. but mHealth is also a double-edged sword as data collection and deeper insight could propel trials off course, according to a report at Hospital & Health Networks.
In an exclusive interview with FierceHealthcare, KIimberly Skelding, M.D., an interventional cardiologist at Geisinger Health System based in Danville, Pennsylvania, discusses efforts by hospitals and physicians around the country to improve equity in healthcare research and delivery.
FierceHealthIT spoke with Glenn Engelmann, senior counsel in the Washington, D.C. law firm of McDermott Will & Emery and a former senior executive with pharmaceutical company AstraZeneca, about the recently launched Open Payments database.
The much-maligned Open Payments database has launched, though it's far from glitch-free.